Publications by authors named "Seyger M"
Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.
Objective: PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis.
Article Synopsis
- Baricitinib, a selective Janus kinase inhibitor, showed positive effects on moderate-to-severe atopic dermatitis in children after 16 weeks in the BREEZE-AD-PEDS study.* -
- The long-term extension study found that a greater percentage of patients on the 4-mg dose achieved significant skin improvement at 52 weeks compared to lower doses and placebo.* -
- Overall, the treatment was mostly safe, with mild to moderate side effects reported and no serious safety issues or new risks identified.*
Article Synopsis
- - The study evaluates the effectiveness and longevity of treatments (dupilumab, methotrexate, and cyclosporine A) for pediatric patients aged 2-17 with severe atopic dermatitis across five centers in the Netherlands from 2013-2023.
- - Out of 502 treatment episodes analyzed, dupilumab showed the highest drug survival rates over three years (84.1% at one year, 72.3% at two, and 62.0% at three), compared to significantly lower rates for methotrexate and cyclosporine A.
- - The main reason for discontinuing treatment was ineffectiveness, especially noted with cyclosporine A, while factors like treatment
Background: Handheld laser speckle contrast imaging (LSCI) is crucial in clinical settings, but motion artifacts (MA) can compromise perfusion image reliability. Current prevention and suppression methods are often impractical or complex. Machine vision techniques, promising in medical imaging, could improve signal quality, but their use in suppressing MA is still unexplored.
View Article and Find Full Text PDFArticle Synopsis
- Telemedicine has become more popular for providing remote healthcare, especially after the COVID-19 pandemic, and may serve as an alternative for routine visits for patients with chronic skin conditions.
- A systematic review of 11 studies (including RCTs) indicates that telemedicine appears to be comparable to in-person consultations for managing chronic inflammatory skin diseases like psoriasis and atopic dermatitis, particularly regarding patient quality of life.
- Despite encouraging results about telemedicine's benefits, such as cost-effectiveness and convenience, further extensive research is needed to solidify these findings and address any uncertainties.
Background And Objective: The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking.
View Article and Find Full Text PDFMutations in proteasome β-subunits or their chaperone and regulatory proteins are associated with proteasome-associated autoinflammatory disorders (PRAAS). We studied six unrelated infants with three de novo heterozygous missense variants in PSMB10, encoding the proteasome β2i-subunit. Individuals presented with T-B-NK± severe combined immunodeficiency (SCID) and clinical features suggestive of Omenn syndrome, including diarrhea, alopecia, and desquamating erythematous rash.
View Article and Find Full Text PDFThe lifestyle of psoriasis patients and their motivation to change.
J Eur Acad Dermatol Venereol
October 2024
Article Synopsis
- Itch is a major symptom of atopic dermatitis (AD) in children, affecting their quality of life, prompting a systematic review and meta-analysis of systemic treatments for itch relief in pediatric patients with AD.
- The study analyzed data from 30 studies, highlighting that treatments like dupilumab, cyclosporin A, abrocitinib, and upadacitinib significantly reduced itch severity, with dupilumab showing the most evidence.
- The findings suggest that these treatments can improve the quality of life for children with AD, emphasizing the need to consider patient-centered goals in treatment decisions as more therapies become available.
Background: Psoriasis is a chronic inflammatory skin disorder that affects 125 million people worldwide, with one-third having childhood onset.
Objectives: The PURPOSE study evaluated long-term safety and effectiveness of etanercept in paediatric psoriasis.
Materials & Methods: This observational study enrolled patients with paediatric psoriasis who were prescribed etanercept per routine care in eight EU countries.
Article Synopsis
- The study investigates the implementation of dose reduction (DR) for biologic treatments in psoriasis patients across three hospitals over six months.
- It found that while the implementation strategy was generally followed, not all healthcare providers utilized the tools provided, indicating areas for improvement.
- Successful implementation of DR was linked to better patient support, guideline integration, and efficient electronic health systems, which helped 50% of eligible patients start DR.
Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis regarding dose reduction is sparse. The objective of this study was therefore to explore patients' perspectives towards dose reduction of biologics for psoriasis.
View Article and Find Full Text PDFIdentification of children at risk for the development of severe paediatric plaque psoriasis: Findings from the prospective observational long-term Child-CAPTURE registry.
J Eur Acad Dermatol Venereol
July 2023
Article Synopsis
- This study addresses the lack of guidelines for biologic dose reduction in psoriasis treatment, aiming for clear criteria to support consistent practices among clinicians.
- An online voting process involving Dutch dermatologists led to consensus on 15 recommendations for dose reduction eligibility, criteria for discontinuation, and specific dosing schedules for commonly used biologics.
- The final recommendations and an implementation algorithm are intended to help doctors make informed decisions about reducing biologic treatment in stable psoriasis patients, improving care consistency for their patients.
Introduction: Skin surface proteins are potential biomarkers in psoriasis and can be measured noninvasively with the transdermal analysis patch (TAP). This study aimed to assess markers measured by TAP over time in daily clinical practice, explore their correlation with disease severity in pediatric psoriasis, and compare the TAP and tape stripping detection capability.
Methods: In this prospective observational daily clinical practice study, pediatric psoriasis patients (aged >5 to <18 years) were followed during 1 year.
Background: The diagnosis of Scleroderma En Coup de Sabre (ECDS)/Parry Romberg Syndrome (PRS) is mainly based on characteristic clinical findings. Methods to objectively monitor the course of the disease in a standardized way are lacking.
Objectives: This descriptive, retrospective, single centre cohort study aims to describe the contribution of 3D photographs in the assessment of the degree of facial asymmetry changes over time in growing children and adolescents with ECDS and PRS.
In paediatric psoriasis, few studies have evaluated methotrexate effectiveness, adverse events and folic acid regimen. Therefore this study prospectively assessed methotrexate adverse events and effectiveness in paediatric patients with psoriasis in a real-world setting. Furthermore, gastrointestinal adverse events and methotrexate effectiveness were compared between folic acid regimens (5 mg once weekly vs 1 mg 6 times weekly).
View Article and Find Full Text PDFObjective: To evaluate the effect of lifestyle changes on the severity of psoriasis and the quality of life in patients with psoriasis.
Methods: For this narrative review, PubMed, Embase and ClinicalTrials.gov were searched for lifestyle intervention studies with an intervention duration of at least 12 weeks.
Importance: About 1% of children and adolescents worldwide are affected by plaque psoriasis.
Objective: To evaluate the long-term efficacy and safety of ixekizumab for pediatric patients with moderate to severe psoriasis.
Design, Setting, And Participants: This multicenter randomized clinical trial (IXORA-PEDS) evaluated pediatric patients with plaque psoriasis.